Journal Scans
Eribulin Monotherapy Versus Treatment of Physician’s Choice in Patients With Metastatic Breast Cancer (EMBRACE): A Phase 3 Open-Label Randomised Study
Eribulin Improves Survival in Metastatic Breast Cancer
J Cortes, J O’Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova, P Chollet, A Manikas, V Diéras, T Delozier, V Vladimirov, F Cardoso, H Koh, P Bougnoux, CE Dutcus, S Seegobin, D Mir, N Meneses, J Wanders, C Twelves
Yes
20110203
2011 Mar 3
Lancet
Eribulin Monotherapy Versus Treatment of Physician’s Choice in Patients With Metastatic Breast Cancer (EMBRACE): A Phase 3 Open-Label Randomised Study
Lancet. 2011 Mar 3;[Epub Ahead of Print], J Cortes, J O’Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova, P Chollet, A Manikas, V Diéras, T Delozier, V Vladimirov, F Cardoso, H Koh, P Bougnoux, CE Dutcus, S Seegobin, D Mir, N Meneses, J Wanders, C Twelves
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action. We aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments. Methods: In this phase 3 open-label study, women with locally recurrent or metastatic breast cancer were randomly allocated (2:1) to eribulin mesilate (1•4 mg/m2...
